Journal
CURRENT HEMATOLOGIC MALIGNANCY REPORTS
Volume 14, Issue 2, Pages 83-93Publisher
CURRENT MEDICINE GROUP
DOI: 10.1007/s11899-019-00501-3
Keywords
T cell acute lymphoblastic leukemia; T-ALL; Relapse; Refractory; Treatment
Categories
Funding
- National Center for Advancing Translational Sciences of the National Institutes of Health [TL1TR001880]
Ask authors/readers for more resources
Purpose of ReviewPatients with relapsed T cell acute lymphoblastic leukemia (T-ALL) have limited therapeutic options and a poor prognosis. Although a variety of salvage chemotherapy regimens may be used, response rates are unsatisfactory. This article summarizes current approaches and promising emerging strategies for the treatment of relapsed T-ALL.Recent FindingsAlthough nelarabine is the only agent approved specifically for T-ALL, recent studies have identified a variety of genetic alterations and signaling pathways that are critical in its pathogenesis. Based on these findings, a number of small-molecule inhibitors and other targeted therapies are being studied for relapsed T-ALL, including gamma-secretase inhibitors, BCL-2 inhibitors, cyclin-dependent kinase inhibitors, and mTOR inhibitors. In addition, pre-clinical studies of chimeric antigen receptor T cells targeting CD5 and CD7 as well as the monoclonal antibody daratumumab have shown promising results for T-ALL.SummaryRelapsed T-ALL currently remains challenging to treat, but recent pre-clinical studies of targeted and immunotherapeutic agents have shown encouraging results. A number of clinical trials investigating these approaches for T-ALL are currently underway.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available